NCT07447206 · Phase 2 · NOT YET RECRUITING
Vascular Intervention Strategies Trial for Alzheimer's
This small pilot study tests whether a pharmacist-led program can manage high blood pressure and high cholesterol in 10 people. Everyone takes an angiotensin receptor blocker for blood pressure and a statin, or a non-statin alternative, for cholesterol over six months. It is a Phase 2 trial, an early check on practicality and safety, not proof that it works.
You may qualify if
- APOE ε4 carrier (homozygote or heterozygote)
- LDL-C of 100-250 mg/dL
- Systolic blood Pressure (SBP) 130-180 mm Hg
- Age 50-75 years
- Fluency in English
- No dementia based on medical record review
- Male or post-menopausal female
You're excluded if
- One minute standing SBP \< 110 mm Hg
- Arm circumference prevents from accurate BP measurement with use of available devices
- Lost weight of > 10% unintendedly (within the past 6 months),
- Contraindications to blood pressure and cholesterol lowering medications
- Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)
- Evidence of dementia based on medical record review
- Living in a skilled nursing or rehabilitation facility
- Receiving palliative or hospice care
- Bipolar illness or schizophrenia
- Drug or alcohol disorder
- Receiving chronic opioid therapy
- Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)
- Severe loss of visual, hearing or communication ability
- Organ transplant
- History of stroke, symptomatic HF or left ventricular ejection fraction \< 35%
- ESRD or eGFR \< 20 ml/min /1.73m2
- Does not consent to be contacted or to have their medical record reviewed for research purposes
- Concurrent participation in another clinical trial
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-05-04